The Patent Finder

Hybridon, Inc.

Also on record
Records under this name other than patents Hybridon, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Hybridon, Inc.

PatentTitleStatus Expires Confidence
US 7,749,975Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
Formerly held
Term ended
Term ended Aug 27, 2026 · From the USPTO record
Term endedTerm ended Aug 27, 2026From the USPTO record
US 7,569,554Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
Formerly held
Term ended
Term ended May 6, 2026 · From the USPTO record
Term endedTerm ended May 6, 2026From the USPTO record
US 8,946,175Stabilized Immunomodulatory Oligonucleotides
Formerly held
Term ended
Ended no later than Oct 10, 2025 · Low confidence
Term endedEnded no later than Oct 10, 2025Low confidence
US 8,716,253Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
Formerly held
Term ended
Term ended Jun 28, 2025 · From the USPTO record
Term endedTerm ended Jun 28, 2025From the USPTO record
US 7,498,426Immunostimulatory oligonucleotide multimers
Formerly held
Term ended
Term ended Apr 29, 2025 · From the USPTO record
Term endedTerm ended Apr 29, 2025From the USPTO record
US 7,427,405Immunostimulatory oligonucleotide multimers
Formerly held
Term ended
Term ended Feb 9, 2025 · From the USPTO record
Term endedTerm ended Feb 9, 2025From the USPTO record
US 7,517,862Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
Formerly held
Term ended
Term ended Jun 9, 2024 · From the USPTO record
Term endedTerm ended Jun 9, 2024From the USPTO record
US 7,407,944Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
Formerly held
Term ended
Term ended Mar 4, 2024 · From the USPTO record
Term endedTerm ended Mar 4, 2024From the USPTO record
US 8,008,267Stabilized immunomodulatory oligonucleotides
Formerly held
Lapsed on the fee record
Ended Aug 30, 2023 · From the USPTO record
Lapsed on the fee recordEnded Aug 30, 2023From the USPTO record
US 7,276,489Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
Formerly held
Term ended
Term ended Jul 29, 2023 · From the USPTO record
Term endedTerm ended Jul 29, 2023From the USPTO record
10 of 147 patents shown.
Pro members see all 147.
Pro members: see all 147 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited